Rocket Pharmaceuticals Granted Fda Fast Track and Orphan Drug Designations for Rp-a601 Gene Therapy in Pkp2 Arrhythmogenic Cardiomyopathy (Acm)
Friday, June 09, 2023
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has recently announced significant developments regarding their gene therapy candidate, RP-A601, for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM). The U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to RP-A601, recognizing its potential in addressing the unmet medical needs of patients with this rare inherited heart disease.
PKP2-ACM is characterized by life-threatening arrhythmias, cardiac structural abnormalities, and sudden cardiac death. The current standard of care for PKP2-ACM, which includes medical therapy, implantable cardioverter defibrillators (ICDs), and ablation procedures, is not curative and does not effectively prevent disease progression or arrhythmia recurrence. RP-A601, an adeno-associated virus (AAV.rh74)-based gene therapy, aims to provide a one-time, potentially curative treatment for PKP2-ACM.
The Fast Track designation granted to RP-A601 by the FDA facilitates its development and expedites the review process. It allows for increased communication with the FDA, potential accelerated approval, priority review, and Rolling BLA Review, which enables the submission of completed sections of the Biologic License Application (BLA) for review instead of waiting for the entire application to be completed.
Additionally, RP-A601 has been designated as an Orphan Drug by the FDA, which supports the development of therapies for rare disorders affecting fewer than 200,000 patients in the U.S. This designation provides benefits such as market exclusivity upon regulatory approval, exemption from FDA application fees, and tax credits for qualified clinical trials.
Rocket Pharmaceuticals has received FDA clearance for the Investigational New Drug (IND) application for RP-A601 based on promising preclinical proof of concept studies that demonstrated reduced arrhythmias and increased survival rates. This milestone makes RP-A601 the first gene therapy in development for PKP2-ACM to receive IND clearance and represents a significant advancement in Rocket's AAV-based cardiovascular gene therapy franchise.
The next step for Rocket Pharmaceuticals is to initiate a Phase 1 clinical trial to evaluate the safety and preliminary efficacy of RP-A601 in adult PKP2-ACM patients at high risk for life-threatening arrhythmias. The trial aims to assess the impact of RP-A601 on various factors related to PKP2-ACM, including PKP2 myocardial protein expression, cardiac biomarkers, clinical predictors of ventricular arrhythmias, and sudden cardiac death.
The Fast Track and Orphan Drug designations for RP-A601 highlight the urgent unmet medical need for effective treatments for PKP2-ACM. If approved, RP-A601 has the potential to significantly improve the survival and quality of life for patients affected by this devastating disease.
